Explore more publications!
Health Times of Rhode Island
Got News to Share?

Health Times of Rhode Island: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

Press releases published on March 4, 2026

Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer
Mar. 4, 2026

Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer

Indeterminate GlobeNewswire
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Mar. 4, 2026

Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea

Indeterminate GlobeNewswire
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
Mar. 4, 2026

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Indeterminate GlobeNewswire
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
Mar. 4, 2026

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Indeterminate GlobeNewswire
Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy
Mar. 4, 2026

Independent study presented at ECR highlights REGENERA™ bioresorbable scaffold potential for breast restoration after lumpectomy

Indeterminate GlobeNewswire
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
Mar. 4, 2026

BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy

Indeterminate GlobeNewswire
DermaFix Nail Fungus Treatment Gel Claims Evaluated in 2026 Market Report Covering Tea Tree Oil Research, Penetration Technology Positioning, and Pricing Transparency
Mar. 4, 2026

DermaFix Nail Fungus Treatment Gel Claims Evaluated in 2026 Market Report Covering Tea Tree Oil Research, Penetration Technology Positioning, and Pricing Transparency

Indeterminate GlobeNewswire
MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify
Mar. 4, 2026

MemoTril Cognitive Support Claims Evaluated: Latest 2026 Consumer Report Examines MemoTril Brain Supplement Ingredients, Memory Enhancement Marketing, and What Consumers Should Verify

Indeterminate GlobeNewswire
Male Power XL "Black Elixir" Claims Evaluated: 2026 Report Examines Ingredient Research, Proprietary Blend Transparency, and What Men Should Verify Before Buying
Mar. 4, 2026

Male Power XL "Black Elixir" Claims Evaluated: 2026 Report Examines Ingredient Research, Proprietary Blend Transparency, and What Men Should Verify Before Buying

Indeterminate GlobeNewswire
AudiLeaf Ear Health Claims Evaluated: 2026 Report Examines Ingredients, Proprietary Blend Dosing, and What Consumers Should Verify Before Buying
Mar. 4, 2026

AudiLeaf Ear Health Claims Evaluated: 2026 Report Examines Ingredients, Proprietary Blend Dosing, and What Consumers Should Verify Before Buying

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions